Highest quality standards are achieved through the implementations of latest technology, decades of experience and everlasting moral values , which have helped us to retain our customers as well as multiply them.
Mission & Vision
JBCPL aims to manufacture affordable products that improve lives across the globe. Providing medicines of the highest quality to our customers, is very much part our mission. We endeavour to please every JBCPL client and stakeholder through focus, hard work and honesty. Our vision is to become one of the leading global generic manufacturers of quality pharmaceutical products by excelling in the fields of research, regulatory and manufacturing.
Innovation
We believe that innovation is essential to developing a world class pharmaceutical company especially in a globalised world. That’s why we aim to develop new products that cater to every population.As diseases change and grow, innovation is the only way to truly succeed. Keeping apace with an ever dynamic health industry is absolutely fundamental to our lives as well to those we are trying to save.
PatentsNDDS patents granted in the United States of America for controlled release formulations of Ranitidine and topical dental formulations of Metronidazole and Chlorhexidine for periodontal treatment
Patents have also been granted in
The US and South African Patent Offices have granted patents for all the NCEs invented by the company in the therapeutic category of NSAID. A similar application has already been forwarded to the European Union Authorities for filing this patent.
International Patents Granted 24
Domestic Patents Granted 15
QualityOur commitment to quality is firm. This is why we run our entire production process with a battery of quality-control tests conducted using state-of-the art laboratory testing equipment. The strict quality assurance standards maintained at every single manufacturing plant have earned certificates for ‘Good Manufacturing Practices’ under the WHO’s GMP certification scheme.
The Company holds DMFs for Diclofenac Sodium, Diclofenac Potassium, Diclofenac Acid and Nifedipine. The manufacturing plant for Diclofenac Sodium, Diclofenac Potassium has been approved by the USFDA.
Additionally, the company’s formulation manufacturing plants at various locations hold approvals from authorities like the USFDA, UK MHRA, TGA Australia, MCC South Africa and authorities from Germany, Latvia, Ukraine and other African countries.
It comes as no surprise that JBCPL is one of the first Asian companies to obtain a Certificate of Suitability to European Pharmacopoeia Monograph for Metronidazole, Nifedipine and Diclofenac Sodium.
With these international accreditations, the company thrives on high-quality standards and its products are truly competitive in the international market.
R & D
TechnologyThe company has 17 manufacturing plants in two cities producing a diverse range of active pharmaceutical ingredients, drug intermediates, pharmaceutical formulations, contrast media and herbal remedies. In response to an ever-competitive global environment, JBCPL has established an ultra-modern export-oriented unit with a unique design that guarantees safety, purity, and quality. The protection of the environment is also a major part of our corporate philosophy. We have effective water and air pollution control systems in all our plants in an effort to minimize all wastage.
Examples of JBCPL’s constant endeavour to stay technologically advanced are:
* To embrace new technologies and methods. * To give unsurpassed products and services to the clients. * To constantly look for improvement and changes.
